The Australian sharemarket has extended a late end of year rally, sidestepping a tech selloff in the US overnight as volumes ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

Email Alerts for: Current price: $2.63 Market cap: $3.93bn Current price: $3.01 Current price: $2.31 Current price: $3.69 ...

Regenerative medicine company Mesoblast Ltd. received an early Christmas present from the FDA for approval of its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil ...

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced the Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L) as the first mesenchymal ...

GEN presents data compiled by Morningstar's Morningstar Direct asset management platform for StockWatch of the top five ...

The U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived ...

Meanwhile, synthetic gel aids in recovery after spinal surgery; Pittsburgh researchers create helper robots for people with ALS; a study finds nerve stimulation is effective against ...

This week’s Bulls N’ Bears Runner of the Week is… icetana. The video analytic solution provider inked a 3-year Malaysian ...

The local bourse hit a three-month low on Friday as CBA led banks down, Mesoblast gave back some of its gains and the ASX had ...

A round up of some stocks capturing attention this week, featuring INOVIQ, Tamboran Resources, Omni Bridgeway, Clarity Pharmaceuticals and Mesoblast.